dappradarnftgames| Hengrui Pharmaceutical (600276.SH): Clinical trial applications for three drugs of subsidiaries have been approved

Zhitong Finance APP News, Hengrui Pharmaceutical (600276dappradarnftgames.SH) issued an announcement that the company's subsidiaries Shanghai Hengrui Pharmaceutical Co., Ltd. and Suzhou Shengdiya Biomedical Co., Ltd. received approval from the State Food and Drug Administration for the issuance of SHR-9839 for injection, SHR-A1921 for injection and SHR-A2009 for injectiondappradarnftgamesThe Drug Clinical Trial Approval Notice will be launched in the near future.

It is reported that SHR-9839 for injection is a humanized antibody drug independently developed by the company. It is intended to be used to treat advanced malignant tumors. It plays an anti-tumor effect by simultaneously blocking two key signal pathways related to the occurrence and development of tumors. At present, no drugs with the same target have been approved for marketing in China.

SHR-A1921 for injection is an antibody-drug conjugate (ADC) that targets TROP2 tumor-associated antigen. After binding to the target antigen on the surface of tumor cells, it enters the cells through endocytosis, and kills tumor cells by releasing small molecule toxins. One similar product has been approved for marketing in China, and many similar drugs are in the clinical development stage, with the main indications for advanced malignant tumors.

SHR-A2009 for injection is an antibody-drug conjugate targeting HER3. It can specifically bind to HER3 on the surface of tumor cells, and then be endocytosed into cells and transported into lysosomes, where it is hydrolyzed to release free toxins, killing tumor cells. No similar drug has been approved for marketing around the world.